SCYNEXIS Inc (SCYX)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$5.30-0.93%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
QuarterlyIQ Insights · SCYX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -50.6% |
| Our one-year growth estimate | diamond | -90.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 39.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 3 industry peers · Company calendar date is not available
SCYX — director transition
Dated 2026-04-20
Director — Steven C. Gilman: Dr. Steven C. Gilman is retiring from the Board of Directors and will not stand for reelection at the 2026 Annual Meeting.
Why it matters: Getting funding is important for SCYNEXIS to grow and run its business.
Supportive ifA notice will say a private placement raised at least $10 million.
Worry ifNo funding was secured or there was a failed funding attempt.
Why it matters: Meeting sales goals for BREXAFEMME is important to show its market value.
Supportive ifSales for BREXAFEMME show big growth or meet sales goals.
Worry ifSales do not meet the expected goals.
Why it matters: Getting funding is important for SCYNEXIS to run its business and grow.
Supportive ifAn announcement that a private funding round is complete.
Worry ifNo funding secured or further delays in the funding process.
Why it matters: Finishing this deal could help SCYNEXIS's products and its place in the market.
Supportive ifA formal announcement that the deal is done.
Worry ifMore delays or canceling the deal announcement.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$253 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $712 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,000 loss on $10,000 · 30.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.